PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics ...
PTC Therapeutics presents new data from Phase 3 APHENITY trial
PTC Therapeutics (PTCT) shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 ...
BioMarin presents studies showing efficacy of Voxzogo, Palynziq
BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...